checkAd

     126  0 Kommentare Dermapharm: Mixed start to the year with missed expectations; PT down, BUY

    Dermapharm Holding SE reported a good start to the year, with decent revenue and profitability performance.

    The full update is avaible on:

    Read

     

    What's it all about ?

    Dermapharm Holding SE (Dermapharm) reported a good start to the year, with decent revenue and profitability performance. Adj. EBITDA witnessed high-teens growth despite strained supply chains, lockdowns in China, and the Russia-Ukraine war. However, the company clearly missed expectations. We continue to believe that the expansion of vaccine production in cooperation with BioNTech SE remains an important growth driver. Furthermore, another growth driver in the Herbal Extracts segment will be the recently acquired cannabis business, which is expected to gain importance in 2022. Even if the overall perspectives are good, we no longer consider the anticipated upper end of the guidance to be achievable. With reduced expectations and generally adjusted model assumptions to reflect possible headwinds in 2022, we are reducing the target price by c. 17% to EUR 70.00 from EUR 84.00. After yesterday's price slump, however, our rating remains a BUY.

    https://www.research-hub.de/disclaimer

    Diskutieren Sie über die enthaltenen Werte


    mwb research AG
    0 Follower
    Autor folgen
    Mehr anzeigen
    Bei der mwb research AG handelt es sich um ein unabhängiges (Aktien)-Analysehaus mit Fokus auf deutschen Nebenwerten (Small & MidCaps).
    Mehr anzeigen
    RSS-Feed abonnieren

    Weitere Artikel des Autors


    Verfasst von mwb research AG
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Dermapharm: Mixed start to the year with missed expectations; PT down, BUY Dermapharm Holding SE (Dermapharm) reported a good start to the year, with decent revenue and profitability performance. Adj. EBITDA witnessed high-teens growth despite strained supply chains, lockdowns in China, and the Russia-Ukraine war. However, the company clearly missed expectations. We continue to believe that the expansion of vaccine production in cooperation with BioNTech SE remains an important growth driver.